Third Harmonic Bio Inc
NASDAQ:THRD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Meiwa Estate Co Ltd
TSE:8869
|
JP |
|
D
|
Datagroup SE
SWB:D6H
|
DE |
Third Harmonic Bio Inc
Total Equity
Third Harmonic Bio Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Third Harmonic Bio Inc
NASDAQ:THRD
|
Total Equity
$285.2m
|
CAGR 3-Years
32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hims & Hers Health Inc
NYSE:HIMS
|
Total Equity
$540.9m
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Bio-Techne Corp
NASDAQ:TECH
|
Total Equity
$2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
Repligen Corp
NASDAQ:RGEN
|
Total Equity
$2.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
33%
|
|
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Total Equity
$3.3B
|
CAGR 3-Years
24%
|
CAGR 5-Years
24%
|
CAGR 10-Years
23%
|
|
Third Harmonic Bio Inc
Glance View
Third Harmonic Bio Inc is a US-based company operating in industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-09-15. Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of medicine for the treatment of allergic and inflammatory diseases. Its lead product candidate, THB001, is a potent and highly selective, oral small molecule wild-type KIT inhibitor in development for the treatment of mast cell-mediated inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a range of allergic and other inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The company has completed Phase Ia clinical trial for THB001, which has demonstrated dose-dependent reductions of serum tryptase, a key biomarker of mast cell activity, which has been shown to correlate with clinical benefit in chronic urticaria patients.
See Also
What is Third Harmonic Bio Inc's Total Equity?
Total Equity
285.2m
USD
Based on the financial report for Dec 31, 2024, Third Harmonic Bio Inc's Total Equity amounts to 285.2m USD.
What is Third Harmonic Bio Inc's Total Equity growth rate?
Total Equity CAGR 3Y
32%
Over the last year, the Total Equity growth was 6%. The average annual Total Equity growth rates for Third Harmonic Bio Inc have been 32% over the past three years .
